Gala vs Noom Med: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

49 providers verified independently·Independent research·How we rank →

Noom Med beats Gala overall, scoring 7.4/10 vs 7.2/10. Noom Med is more affordable at $99/mo vs $149/mo. Choose Gala for tirzepatide-first patients who want a low-cost compounded pa. Choose Noom Med for users who want a tiered entry into glp-1 care — from $99/mo .

A side-by-side comparison of Gala and Noom Med covering pricing, scores, medication types, insurance, and more to help you decide.

Gala

#40 of 49

7.2/10

Telehealth platform focused on compounded tirzepatide — both microdose and full-dose tiers — alongside a brand-name semaglutide (Ozempic) path and a 'coming soon' Wegovy pill. Operated by AI Coaching, Inc. (Wilmington, DE), backed by OpenLoop-affiliated medical groups (a recognized US telehealth backend) and LegitScript verified. Differentiator: a dedicated 'Gala GLP-1 Tracker' iOS + Android app for in-treatment dosing, weight, and side-effect logging.

Visit Gala

Higher Rated

Noom Med

#28 of 49

7.4/10

Noom restructured Noom Med in 2026 into 3 tiers: $69/mo branded telehealth (med out-of-pocket), $99-149/mo Microdose GLP-1Rx (low-dose + biomarker monitoring), and the Full GLP-1Rx program ($149 intro → $349/mo on 12-week subscription). Coaching app included at every tier.

Visit Noom Med

Feature	Gala	Noom Med
Our Score	7.2/10	7.4/10
Starting Price	$149/mo	$99/mo
Medication Type	Both	Both
Insurance Accepted	No	Yes
Best For	Tirzepatide-first patients who want a low-cost compounded path (microdose $149/mo or full-dose $179-199/mo) plus a dedicated iOS + Android tracker app for daily progress logging	Users who want a tiered entry into GLP-1 care — from $99/mo Microdose all-in (low-dose + biomarkers + coaching) up to a full $349/mo medication + coaching program
Ranking	#40	#28

Pros & Cons Compared

Gala

Pros

+Microdose compounded tirzepatide at $149/mo — the cheapest microdose tirz on a tracked telehealth platform; full-dose compounded tirzepatide at $179/mo (yearly plan) or $199/mo (3-month plan)
+Dedicated 'Gala GLP-1 Tracker' on BOTH iOS and Android — first-party in-treatment logging is uncommon among compounded-only platforms
+OpenLoop-affiliated medical groups + LegitScript verification provide third-party accountability that many compounded-only platforms lack
+All 50 states, free shipping, no insurance required, 24/7 patient support claimed

Cons

−Brand-name Ozempic pricing ($1,299/mo) is materially above market — NovoCare direct pricing for Wegovy is $349/mo, Hers offers Wegovy at $149/mo via the 2026 Novo Nordisk partnership
−Tirzepatide-only on the compounded side — compounded semaglutide is NOT offered, narrower medication menu than peers like Maximus, Ro, or Henry Meds
−Mixed Trustpilot reviews mention dosing inconsistencies and slow customer service responsiveness — verify your specific dose and batch with each refill
−Initial consultation typically a sync video visit, but ongoing follow-ups and questions are chat-based (no scheduled ongoing video access) — and no published labs, no named medical director, no specialty obesity oversight
−Restrictive refund policy — Gala's published terms state 'IN NO EVENT SHALL YOU BE ISSUED A REFUND UPON CANCELLATION OF THE SUBSCRIPTION SERVICES' with a narrow exception for provider-initiated medical disqualification. No money-back guarantee. Read the published policy at galaglp1.com/refund-policy before enrolling on a commitment plan
−Newer brand under AI Coaching, Inc. (founded 2024 per LinkedIn) — limited public company history; founders, founding year, and named medical director not publicly disclosed on galaglp1.com itself

Noom Med

Pros

+Tiered 2026 entry — $69/mo branded telehealth tier lets users start with just medication access and the coaching app
+New Microdose GLP-1Rx program ($99-149/mo) — low-dose GLP-1 + biomarker monitoring for sensitive users
+Insurance accepted for qualifying plans — can significantly reduce out-of-pocket costs on brand-name meds
+Industry-leading behavioral coaching app with years of psychology-based weight loss methodology

Cons

−Tiered pricing creates confusion — $69, $99-149, or $149-349 depending on tier
−Full GLP-1Rx program requires 12-week subscription ($149 intro rate applies only for the first few weeks)
−Medication costs on the $69 tier are out-of-pocket — the low tier price is just the platform
−App coaching still requires real engagement — skip-prone users waste the behavioral value

Our Verdict

Noom Med edges out Gala with a score of 7.4/10 vs 7.2/10. If budget is your priority, Noom Med starts at $99/mo compared to Gala's $149/mo. Noom Med accepts insurance, which can significantly reduce your out-of-pocket costs. Choose Gala if you want: tirzepatide-first patients who want a low-cost compounded path (microdose $149/mo or full-dose $179-199/mo) plus a dedicated ios + android tracker app for daily progress logging. Choose Noom Med if you want: users who want a tiered entry into glp-1 care — from $99/mo microdose all-in (low-dose + biomarkers + coaching) up to a full $349/mo medication + coaching program.

Still undecided? Editor's #1 Overall Pick

Embody

$299/mo · 7.3/10 · Compounded

If neither Gala nor Noom Med feels like the right fit, our overall #1 pick across all 49 GLP-1 telehealth providers is Embody — strongest balance of clinical oversight, transparent pricing, and verified availability.

Visit Embody→Read our full Embody review